Reports record-high revenues since inceptionMONTREAL, March 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty ...
Q4 2024 Earnings Call Transcript March 20, 2025 Autolus Therapeutics plc beats earnings expectations. Reported EPS is $-0.09, ...
Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...
Regulatory and reimbursement pathways should consider indirect benefits in addition to direct health benefits when evaluating ...
Clinical hold lifted for late stage cadisegliatin program for diabetesCATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to ...
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected ...
Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell ...
A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appo ...
We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...
Knight Therapeutics Inc. ( OTCPK:KHTRF) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Samira Sakhia - President and Chief Executive Officer Arvind Utchanah - Chief Financial Officer Amal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback